Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over

  • Technology appraisal guidance
  • TA967
  • Published: 

History

Documents created during the development process.

Final draft guidance

Declaration of interests

Committee meetings

Invitation to participate